Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

NCT07108387 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

78

Enrollment

NIH

Sponsor class

Conditions

Giant Cell Arteritis (GCA)

Interventions

DRUG: Tocilizumab
DRUG: Discontinue Tocilizumab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)